First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in > 2000 Patients (Pts). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Thomssen, C
  • Pierga, J-Y
  • Pritchard, Kathleen
  • Biganzoli, L
  • Cortes-Funes, H
  • Petrakova, K
  • Kaufman, B
  • Smith, IE

publication date

  • December 15, 2009